RenovoRx (RNXT) AGP Emerging AgBiotech/Bio-Solutions summary

Company overview and technology

• Focuses on interventional oncology with a late-stage product and a commercialized catheter device.

• Developed TAMP (Trans-Arterial Micro-Perfusion), a localized chemotherapy delivery system.

• Catheter device is FDA-cleared and began commercialization in 2025, targeting a $400M peak sales opportunity.

• Platform is protected by patents extending to 2043.

• Device is used in a variety of solid tumors, overcoming chemo resistance in difficult-to-treat cancers.

Commercialization and market strategy

• Achieved $900,000 in revenue through Q3 2025 without a dedicated sales force.

• Targeting 200 specialized hospitals in the U.S. with a small, focused sales team.

• Hired senior sales and marketing leadership in Q3 and expanding team for 2026 market penetration.

• Each patient typically undergoes 5–10 procedures, representing $50,000–$100,000 in revenue per patient.

• Building a pipeline with 5 active sites, 9 approved, 20 in process, and 30–40 expressing interest.

Clinical development and trial progress

• Phase III TIGeR-PaC trial for locally advanced pancreatic cancer nearing enrollment completion, with final data expected in 2027.

• Interim analysis showed a 6-month survival benefit and 65% reduction in systemic toxicities.

• Post-marketing registry study launched to collect real-world data across multiple cancer types.

• Investigator-initiated trials underway in metastatic and early-stage pancreatic cancer.

• No major changes to trial design; primary endpoint analysis method clarified as Wilcoxon.